Martek Biosciences Corp. 

(Public, NASDAQ:MATK)   Watch this stock   
Find more results for MATK
Sep 23, 2009
CanaccordAdams Healthy Living Conference
Sep 21, 2009
UBS Global Life Sciences Conference
Sep 2, 2009
Q3 2009 Earnings Conference Call
Sep 2, 2009
Q3 2009 Earnings Release
More events from AOL Finance »    

Key stats and ratios

Q3 (Jul '09) 2008
Net profit margin 11.47% 10.69%
Operating margin 18.27% 15.94%
EBITD margin - 24.15%
Return on average assets 5.33% 6.06%
Return on average equity 5.79% 6.72%
Employees 569 -

Address

6480 Dobbin Road
Columbia, MD 21045
United States - Map
+1-410-7400081 (Phone)
+1-410-7402985 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

Martek Biosciences Corp. discussed on blogs

Ranking 1300+ Small Cap Stocks by Cash Flow Per Share - NASD100 ... - Investor's Resources - NASD100.com - Daily Stock Rankings - 10 hours ago
Stock Picks For Monday: Nanometrics, Melco Crown Entertainment ... - Antonio Costa - Daily Markets - 14 hours ago

Martek Biosciences Corp. discussions

  View all discussions »

Description

Martek Biosciences Corporation (Martek) develops omega-3 docosahexaenoic acid (DHA) products. The Company produces life’sDHA, a vegetarian source of the omega-3 fatty acid DHA, for use in infant formula, pregnancy and nursing products, foods and beverages, dietary supplements and animal feed, and life’sARS, a vegetarian source of the omega-6 fatty acid, arachidonic acid (ARA) for use in infant formula. The Company has developed production methods for two fatty acids, DHA and ARA. It sells oils containing these fatty acids under the names life’sDHA, DHASCO, Neuromins, ARASCO and life’sARA. Martek derives DHA from microalgae and ARA from fungi, using its own processes. The Company has entered into license agreements with 30 infant formula manufacturers. Its licensees include infant formula manufacturers, such as Mead Johnson Nutritionals, Nestle, Abbott Laboratories, Wyeth and Danone, each of whom is selling infant formula supplemented with Martek’s nutritional oils.

Officers and directors

Robert J. Flanagan
Chairman of the Board
Age: 52
Bio & Compensation - Reuters
Steve Dubin
Chief Executive Officer, Director
Age: 55
Bio & Compensation - Reuters
David M. Abramson
President
Age: 55
Bio & Compensation - Reuters
Peter L. Buzy
Chief Financial Officer, Executive Vice President - Finance and Administration, Treasurer
Age: 49
Bio & Compensation - Reuters
Peter A. Nitze
Chief Operating Officer, Executive Vice President
Age: 50
Bio & Compensation - Reuters
David M. Feitel
Senior Vice President, General Counsel
Age: 45
Bio & Compensation - Reuters
Barney B. Easterling
Senior Vice President - Manufacturing
Age: 63
Bio & Compensation - Reuters
Tim Fealey Ph.D.
Senior Vice President, Chief Innovation Officer
Age: 64
Bio & Compensation - Reuters
Douglas J. MacMaster Jr.
Director
Age: 78
Bio & Compensation - Reuters
Eugene H. Rotberg
Director
Age: 79
Bio & Compensation - Reuters